

# Nelson L Michael

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/422436/publications.pdf>

Version: 2024-02-01

142  
papers

18,282  
citations

28274

55  
h-index

13379

130  
g-index

152  
all docs

152  
docs citations

152  
times ranked

14186  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. <i>New England Journal of Medicine</i> , 2009, 361, 2209-2220.	27.0	2,748
2	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. <i>New England Journal of Medicine</i> , 2012, 366, 1275-1286.	27.0	1,699
3	Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. <i>Nature</i> , 2014, 512, 74-77.	27.8	527
4	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. <i>Science</i> , 2016, 353, 1129-1132.	12.6	461
5	Vaccine protection against Zika virus from Brazil. <i>Nature</i> , 2016, 536, 474-478.	27.8	460
6	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. <i>Nature</i> , 2012, 482, 89-93.	27.8	452
7	Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. <i>Science Translational Medicine</i> , 2014, 6, 228ra39.	12.4	412
8	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. <i>Nature</i> , 2012, 490, 417-420.	27.8	405
9	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	14.3	374
10	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9019-9024.	7.1	371
11	Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines. <i>Science Translational Medicine</i> , 2014, 6, 228ra38.	12.4	367
12	Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. <i>Journal of Virology</i> , 2012, 86, 11521-11532.	3.4	357
13	Influence of HLA-C Expression Level on HIV Control. <i>Science</i> , 2013, 340, 87-91.	12.6	352
14	Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. <i>Cell</i> , 2013, 155, 531-539.	28.9	334
15	SARS-CoV-2 Variants in Patients with Immunosuppression. <i>New England Journal of Medicine</i> , 2021, 385, 562-566.	27.0	333
16	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015, 163, 988-998.	28.9	326
17	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 330-341.	27.0	314
18	Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection. <i>PLoS ONE</i> , 2012, 7, e33948.	2.5	276

#	ARTICLE	IF	CITATIONS
19	Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2012, 206, 431-441.	4.0	273
20	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018, 392, 232-243.	13.7	269
21	Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. <i>Nature Medicine</i> , 2018, 24, 923-926.	30.7	263
22	Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e87572.	2.5	248
23	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016, 540, 284-287.	27.8	246
24	COMPASS identifies T-cell subsets correlated with clinical outcomes. <i>Nature Biotechnology</i> , 2015, 33, 610-616.	17.5	232
25	Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. <i>New England Journal of Medicine</i> , 2016, 374, 2120-2130.	27.0	229
26	Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation. <i>PLoS Pathogens</i> , 2014, 10, e1004543.	4.7	218
27	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e75665.	2.5	214
28	Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 531-537.	9.1	201
29	Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies. <i>Journal of Virology</i> , 2014, 88, 12385-12396.	3.4	198
30	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016, 22, 762-770.	30.7	197
31	HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART. <i>EBioMedicine</i> , 2016, 11, 68-72.	6.1	193
32	A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 23652-23662.	7.1	193
33	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1444-1457.	1.1	191
34	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. <i>Journal of Virology</i> , 2014, 88, 7715-7726.	3.4	169
35	Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. <i>Lancet, The</i> , 2018, 391, 563-571.	13.7	165
36	Host Determinants of HIV-1 Control in African Americans. <i>Journal of Infectious Diseases</i> , 2010, 201, 1141-1149.	4.0	145

#	ARTICLE	IF	CITATIONS
37	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	12.8	137
38	Elevated <i>HLA-A</i> expression impairs HIV control through inhibition of NKG2A-expressing cells. <i>Science</i> , 2018, 359, 86-90.	12.6	135
39	Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. <i>PLoS Pathogens</i> , 2017, 13, e1006487.	4.7	129
40	Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	108
41	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 3879-3890.	8.2	99
42	Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. <i>Journal of Virology</i> , 2013, 87, 1554-1568.	3.4	97
43	Delayed differentiation of potent effector CD8 <sup>+</sup> T cells reducing viremia and reservoir seeding in acute HIV infection. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	95
44	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. <i>Cell Reports</i> , 2021, 37, 110143.	6.4	94
45	A novel acute HIV infection staging system based on 4th generation immunoassay. <i>Retrovirology</i> , 2013, 10, 56.	2.0	93
46	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV</i> , 2018, 5, e366-e378.	4.7	86
47	Prospects for a Zika Virus Vaccine. <i>Immunity</i> , 2017, 46, 176-182.	14.3	79
48	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016, 2, 43-48.	0.5	73
49	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e297-e306.	4.7	73
50	Accelerating Development of SARS-CoV-2 Vaccines – The Role for Controlled Human Infection Models. <i>New England Journal of Medicine</i> , 2020, 383, e63.	27.0	73
51	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	73
52	Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia. <i>Journal of Virology</i> , 2015, 89, 7494-7505.	3.4	70
53	Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	69
54	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. <i>Immunity</i> , 2014, 41, 909-918.	14.3	65

#	ARTICLE	IF	CITATIONS
55	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. <i>PLoS Pathogens</i> , 2017, 13, e1006510.	4.7	63
56	The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC in Rhesus Monkeys. <i>Journal of Virology</i> , 2014, 88, 1809-1814.	3.4	62
57	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. <i>Nature Medicine</i> , 2020, 26, 228-235.	30.7	61
58	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1255-1263.	4.0	57
59	Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. <i>EBioMedicine</i> , 2014, 1, 37-45.	6.1	55
60	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. <i>PLoS ONE</i> , 2017, 12, e0180720.	2.5	55
61	Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. <i>Journal of Clinical Investigation</i> , 2019, 129, 3361-3373.	8.2	54
62	Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. <i>Journal of Clinical Investigation</i> , 2018, 128, 1903-1912.	8.2	52
63	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>PLoS Computational Biology</i> , 2015, 11, e1003973.	3.2	51
64	Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. <i>Journal of Virus Eradication</i> , 2015, 1, 116-122.	0.5	50
65	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. <i>Nature Medicine</i> , 2015, 21, 1139-1141.	30.7	50
66	Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13439-13444.	7.1	49
67	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	12.4	47
68	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. <i>Npj Vaccines</i> , 2021, 6, 129.	6.0	47
69	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	46
70	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016, 2, 43-48.	0.5	45
71	Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination. <i>Nature Communications</i> , 2018, 9, 1212.	12.8	44
72	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	44

#	ARTICLE	IF	CITATIONS
73	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020, 26, 498-501.	30.7	43
74	Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to $\alpha 4\beta 7$ Integrin Receptor. <i>PLoS ONE</i> , 2015, 10, e0143895.	2.5	41
75	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. <i>Nature Immunology</i> , 2021, 22, 1503-1514.	14.5	40
76	Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection. <i>Blood</i> , 2013, 121, 1136-1144.	1.4	38
77	Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection. <i>Nature Communications</i> , 2020, 11, 272.	12.8	38
78	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. <i>PLoS Pathogens</i> , 2017, 13, e1006182.	4.7	38
79	Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation. <i>Journal of the International AIDS Society</i> , 2016, 19, 21163.	3.0	37
80	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , 2020, 20, 1061-1070.	9.1	36
81	Innate and Adaptive Immune Responses Both Contribute to Pathological CD4 T Cell Activation in HIV-1 Infected Ugandans. <i>PLoS ONE</i> , 2011, 6, e18779.	2.5	36
82	Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. <i>Journal of Virus Eradication</i> , 2015, 1, 116-122.	0.5	36
83	SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. <i>Npj Vaccines</i> , 2021, 6, 151.	6.0	36
84	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018, 218, 633-644.	4.0	35
85	Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant. <i>Npj Vaccines</i> , 2017, 2, 13.	6.0	34
86	Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16 $\alpha$ "STING" Type I IFN Pathway and AIM2 Sensor. <i>Journal of Immunology</i> , 2017, 199, 3293-3305.	0.8	33
87	Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. <i>Journal of Clinical Investigation</i> , 2020, 130, 2845-2858.	8.2	31
88	Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. <i>Nature Communications</i> , 2019, 10, 863.	12.8	27
89	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	26
90	Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. <i>PLoS Pathogens</i> , 2018, 14, e1006888.	4.7	26

#	ARTICLE	IF	CITATIONS
91	Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. <i>Journal of Virology</i> , 2016, 90, 4005-4016.	3.4	25
92	Sequential Dysfunction and Progressive Depletion of <i>Candida albicans</i> -Specific CD4 T Cell Response in HIV-1 Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005663.	4.7	25
93	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. <i>Journal of Clinical Investigation</i> , 2020, 130, 3299-3304.	8.2	24
94	Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R $\alpha^+$ Transcriptional Signature Express Fc $\gamma$ RIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Immunology</i> , 2019, 203, 2210-2221.	0.8	23
95	Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 16, 206-216.	3.3	22
96	Quality Monitoring of HIV-1-Infected and Uninfected Peripheral Blood Mononuclear Cell Samples in a Resource-Limited Setting. <i>Vaccine Journal</i> , 2010, 17, 910-918.	3.1	20
97	Full-length next-generation sequencing of HLA class I and II genes in a cohort from Thailand. <i>Human Immunology</i> , 2018, 79, 773-780.	2.4	20
98	Effect of cytokines on Siglec-1 and HIV-1 entry in monocyte-derived macrophages: the importance of HIV-1 envelope V1V2 region. <i>Journal of Leukocyte Biology</i> , 2016, 99, 1089-1106.	3.3	19
99	A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. <i>Journal of Immunological Methods</i> , 2018, 462, 74-82.	1.4	19
100	The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes. <i>PLoS Computational Biology</i> , 2019, 15, e1007056.	3.2	19
101	Disclosure of Same-Sex Sexual Practices to Family and Healthcare Providers by Men Who Have Sex with Men and Transgender Women in Nigeria. <i>Archives of Sexual Behavior</i> , 2021, 50, 1665-1676.	1.9	19
102	Time to change the paradigm: limited condom and lubricant use among Nigerian men who have sex with men and transgender women despite availability and counseling. <i>Annals of Epidemiology</i> , 2019, 31, 11-19.e3.	1.9	18
103	B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 564-578.e9.	11.0	18
104	Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand. <i>Journal of the International AIDS Society</i> , 2017, 20, 21652.	3.0	16
105	Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection. <i>Cells</i> , 2019, 8, 902.	4.1	15
106	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the <i>Cynomolgus</i> Macaque Coronavirus Disease 2019 (COVID-19) Model. <i>Vaccines</i> , 2022, 10, 717.	4.4	15
107	HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. <i>Immunogenetics</i> , 2014, 66, 299-310.	2.4	14
108	Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. <i>PLoS ONE</i> , 2018, 13, e0194266.	2.5	14

#	ARTICLE	IF	CITATIONS
109	Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. <i>ELife</i> , 2021, 10, .	6.0	12
110	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. <i>JCI Insight</i> , 2020, 5, .	5.0	12
111	IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees. <i>JCI Insight</i> , 2020, 5, .	5.0	12
112	Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. <i>Nature Communications</i> , 2022, 13, .	12.8	12
113	Human Primary Macrophages Derived In Vitro from Circulating Monocytes Comprise Adherent and Non-Adherent Subsets with Differential Expression of Siglec-1 and CD4 and Permissiveness to HIV-1 Infection. <i>Frontiers in Immunology</i> , 2017, 8, 1352.	4.8	11
114	Expansion of Stem Cell-Like CD4 <sup>+</sup> Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression. <i>Journal of Virology</i> , 2019, 93, .	3.4	11
115	A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials. <i>Lancet HIV</i> , 2021, 8, e449-e452.	4.7	11
116	Neurocognitive impact of Zika virus infection in adult rhesus macaques. <i>Journal of Neuroinflammation</i> , 2022, 19, 40.	7.2	11
117	Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 640190.	4.8	10
118	Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes. <i>EBioMedicine</i> , 2021, 63, 103175.	6.1	10
119	Modeling HIV-1 Latency Using Primary CD4 <sup>+</sup> T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy. <i>Journal of Virology</i> , 2019, 93, .	3.4	9
120	Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors. <i>Frontiers in Immunology</i> , 2021, 12, 682120.	4.8	9
121	Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 348-355.	2.1	7
122	Next-generation sequencing of HIV-1 single genome amplicons. <i>Biomolecular Detection and Quantification</i> , 2019, 17, 100080.	7.0	7
123	CTL Clonotypes with Higher TCR Affinity Have Better Ability to Reduce the HIV Latent Reservoir. <i>Journal of Immunology</i> , 2020, 205, 699-707.	0.8	7
124	Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice. <i>PLoS Pathogens</i> , 2021, 17, e1009673.	4.7	7
125	Nautilus: A Bioinformatics Package for the Analysis of HIV Type 1 Targeted Deep Sequencing Data. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1361-1364.	1.1	6
126	Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. <i>Cells</i> , 2019, 8, 365.	4.1	6

#	ARTICLE	IF	CITATIONS
127	Targeted deep sequencing of HIV-1 using the IonTorrentPGM platform. <i>Journal of Virological Methods</i> , 2014, 205, 7-16.	2.1	5
128	Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations. <i>PLoS ONE</i> , 2016, 11, e0146196.	2.5	5
129	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2022, 96, JV10159921.	3.4	5
130	HIV-1 infections with multiple founders associate with the development of neutralization breadth. <i>PLoS Pathogens</i> , 2022, 18, e1010369.	4.7	5
131	HLA-B*46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype. <i>Cell Host and Microbe</i> , 2022, 30, 1173-1185.e8.	11.0	5
132	Factors influencing estimates of HIV-1 infection timing using BEAST. <i>PLoS Computational Biology</i> , 2021, 17, e1008537.	3.2	4
133	Factors associated with testing for HIV and hepatitis C among behaviorally vulnerable men in Germany: a cross-sectional analysis upon enrollment into an observational cohort. <i>AIDS Research and Therapy</i> , 2021, 18, 52.	1.7	4
134	Cautious optimism for HIV vaccine science. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 367-368.	3.8	3
135	Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. <i>Human Immunology</i> , 2022, 83, 53-60.	2.4	3
136	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. <i>Virus Evolution</i> , 2021, 7, veab057.	4.9	2
137	Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. <i>Journal of Virology</i> , 2021, 95, e0079721.	3.4	2
138	Clinical trial design: The nobility of randomization. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	2
139	Preferential and persistent impact of acute HIV-1 infection on CD4 <sup>+</sup> iNKT cells in colonic mucosa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	2
140	Cross-Cutting Lessons Learned During the COVID-19 Pandemic—the Walter Reed Army Institute of Research Experience. <i>Military Medicine</i> , 2021, , .	0.8	2
141	Dynamics of Human Immunodeficiency Virus-1 Genetic Diversification During Acute Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa429.	0.9	1
142	Simplified steps to heterologous prime-boost HIV vaccine development?. <i>Journal of Clinical Investigation</i> , 2019, 129, 4572-4573.	8.2	1